Silence Therapeutics (SLN) Non-Current Assets (2018 - 2026)

Silence Therapeutics (SLN) has 9 years of Non-Current Assets data on file, last reported at $12.3 million in Q1 2026.

• For the quarter ending Q1 2026, Non-Current Assets fell 20.87% year-over-year to $12.3 million; the trailing twelve-month figure through Mar 2026 stood at $12.3 million (down 20.87% YoY), and the FY2025 full-year result was $12.8 million, down 16.27% from the prior year.
• Non-Current Assets eased to $12.3 million in Q1 2026, from $12.8 million in the prior quarter.
• In the past five years, Non-Current Assets ranged from a high of $16.7 million in Q2 2025 to a low of -$113.4 million in Q4 2022.
• A 5-year average of -$16.0 million and a median of $13.0 million in 2025 frame the typical range for Non-Current Assets.
• Across the five-year window, Non-Current Assets jumped 115.18% in 2024 and dropped 20.87% in 2026, its largest moves.
• Tracing SLN's Non-Current Assets over 5 years: stood at -$113.4 million in 2022, then advanced by 11.33% to -$100.6 million in 2023, then jumped by 115.18% to $15.3 million in 2024, then retreated by 16.27% to $12.8 million in 2025, then slipped by 4.01% to $12.3 million in 2026.
• Business Quant data shows SLN's Non-Current Assets at $12.3 million in Q1 2026, $12.8 million in Q4 2025, and $13.2 million in Q3 2025.